Kornimate/medical-research-clean huggingface dataset:
bst-dermon versus standard of care in the treatment of diabetic foot ulcers

Conditions: Diabetic Foot Ulcer

Summary: this trial is designed to investigate the therapeutic benefits of using bst-dermon for the wound repair of diabetic neuropathic foot ulcers. the objective of this study is to evaluate the safety and efficacy of bst-dermon in providing a clinically significant advantage over the standard of care in the repair of diabetic foot ulcers.

this trial is designed to investigate the therapeutic benefits of using bst-dermon for the wound repair of diabetic neuropathic foot ulcers. bst-dermon is a sterile, non-toxic, nonpyrogenic wound dressing composed of an aqueous mixture of chitosan, hydrochloric acid (hcl) and disodium beta-glycerol phosphate (β-gp) designed to address current wound healing needs. chitosan has well documented wound healing properties as well as inherent haemostatic and bacteriostatic capabilities. bst-dermon is used in conjunction with a defined standard of care and is applied over a prepared and debrided ulcer and covered with a semi-occlusive secondary dressing. this prospective, multi-center, randomized, controlled study will enrol 130 type 1 or type 2 diabetic subjects presenting with a grade 1 or grade 2 (wagner classification) diabetic foot ulcer of 1-10cm² on the mid or forefoot. subjects who meet the eligibility criteria will be assigned to one of two groups: 1. a control group that will receive the standard of care or 2. a treatment group that will receive bst-dermon. treatments in both groups will be applied three (3) times a week for up to twenty consecutive weeks or until the study ulcer is closed. all subjects will be followed for safety and efficacy during treatment visits through a final evaluation visit. there will be a post treatment follow-up visit at 4 weeks post-closure for subjects with complete re-epithelialization. the objective of this study is to evaluate the safety and efficacy of bst-dermon in providing a clinically significant advantage over the standard of care in the repair of diabetic foot ulcers.

Eligibility criteria:
inclusion criteria: * between eighteen (18) and eighty (80) years of age * type 1 or type 2 diabetes mellitus * diabetes is under adequate control * diabetic foot ulcer located on the mid or forefoot * diabetic foot ulcer has been present for at least four (4) weeks and no more than two (2) years prior to screening * diabetic foot ulcer is ≥ 1.0cm² and ≤10cm² in size * diabetic foot ulcer is grade 1 or 2 according to the wagner grading system. exclusion criteria: * ulcer is over an active charcot deformity of the mid-foot ("rocker-bottom foot") or over the talus, distal calcaneous, navicular, or cuboid bones or a deformity that interfere with off-loading in the opinion of the investigator * ulcer due to a non-diabetic aetiology * ulcer has tunnels or sinus tracts that cannot be completely debrided. * clinical evidence of infection * osteomyelitis * subject has vasculitis, severe rheumatoid arthritis, other collagen or vascular diseases or other medical conditions, outside of diabetes, known to impair wound healing.

Keywords: diabetic foot ulcer neuropathic chitosan
5-fluorouracil for treatment of stable vitiligo

Conditions: Vitiligo

Summary: vitiligo, a significant dermatologic challenge affecting 0.5 to 2% of the global population. despite various existing medical approaches, current vitiligo treatments are still far from optimal.

vtiligo, a significant dermatologic challenge affecting 0.5 to 2% of the global population. despite various existing medical approaches, current vitiligo treatments are still far from optimal. 5fu is a well-known chemotherapeutic agent that has been used for colorectal cancer treatment. the drug prevents dna synthesis by inhibiting the thymidylate synthetase. the hyperpigmenta-tion of the skin is the most side effect observed with 5-fu therapy which directed its use in treat-ment of vitiligo. besides, many studies reported that 5-fu could induce regimentation in vitiligo by direct stimulation of melanocytes and increasing melanosomes numbers in the keratinocytes.

Eligibility criteria:
inclusion criteria: * patients with stable vitlligo exclusion criteria: * patients under the age of 10 years. * individuals with a history of the koebner phenomenon, a tendency for keloid or hypertrophic scarring * pregnancy. * recent isotretinoin therapy within the last 6 months.

Keywords: 5fu film forming gel vitiligo jak3 gene expression dermabrasion
evaluation of right ventricular systolic function by tapse parameter from subcostal view

Conditions: Transthoracic Echocardiography

Summary: the purpose of this study is to validate a new echocardiographic parameter evaluating right ventricular function.

the key conventional echocardiographic parameter evaluating right ventricular systolic function is the tricuspid annular plane systolic excursion (tapse). it is measured in apical four chamber view by conventional m-mode imaging. other echocardiographic parameters of right ventricular systolic function (fractional area change; tricuspid lateral annular systolic velocity; right ventricular index of myocardial performance) are evaluated in apical four chamber view as well. however, this view might not be clearly visible in the clinical setting of critical illness and subcostal view is often preferred for its higher quality. unfortunately, conventional m-mode can not be used for measurement in this view but anatomical m-mode imaging can. therefore, the investigators decided to evaluate whether tapse measured in subcostal view by anatomical m-mode (stapse) correlates with conventional tapse and whether reliably reflects systolic right ventricular function.

Eligibility criteria:
inclusion criteria: * inpatients * all patients hospitalised in intensive care unit indicated for transthoracic echocardiography examination exclusion criteria: * age \<18 years * insufficient imaging quality of transthoracic echocardiography * refusal of echocardiographic examination by patient
long-term outcome of general anesthesia on dysgnosia

Conditions: Delirium,; Dementia,; Amnestic,; Cognitive Disorders

Summary: cognitive disorders in patients underwent general anesthesia are discussed for decades, but whether there were precise relationship between general anesthesia and dysgnosia is yet to be guaranteed. although controversial data reported from experimental studies in animals, the investigators still proposed that general anesthetics could impair the normally organized system of the central nervous system, which finally displayed a dysfunction of cognition after general anesthesia in a short- or long-term period. therefore, different types of general anesthetics such as inhalational anesthetics and intravenous anesthetics, the investigators hypothesized, had a long-term influence on patients' cognitive ability.


Eligibility criteria:
inclusion criteria: * patients with informed consents * without basal disorders of neurology and psychiatrics exclusion criteria: * with the history of cognitive disorders * with chronic neurological disorders * cannot communicate with investigators * cannot stand general anesthesia

Keywords: cognitive disorders general anesthesia sevoflurane propofol memory
care - quality improvement in asthma secondary prevention in primary care, through delegation of consultations to the nurse.

Conditions: Asthma

Summary: quality improvement in primary care: delegation of check-ups to nurses in general practice


Eligibility criteria:
inclusion criteria: * diagnosed with asthma exclusion criteria: * patients with copd

Keywords: quality development project primary care nurses asthma patient compliance follow-up
descriptive study of the initial management of young children with moderate acute bronchiotitis with home hospitalisation

Conditions: Bronchiolitis; Bronchiolitis Acute

Summary: the occurrence of a first episode of acute bronchiolitis in an infant or young child (3 months-2 years) always represents a medical event that generates stress for parents and in some cases for the primary care physician when it is necessary to decide on the child's orientation for treatment. each year, during the winter season, this pathology affects 30% of infants under two years old (480,000 annual cases in france), generates approximately 30,000 hospitalizations and exposes to an overall mortality risk of 0.08%. according to the recommendations of the has (2019), moderate bronchiolitis does not require systematic hospitalization and can be managed in a home hospitalization (had) context. when the child's examination data do not find signs of severity, the spo2 measurement is greater than 92% and the family context allows for return home, had management is a reasonable option and represents an alternative to the classic scheme of assessing the level of severity by the emergency department and subsequent hospitalization if necessary. had management is carried out within the framework of a very structured "patient pathway", codified and supervised by the pediatric teams and doctors of this department. this patient pathway concerns children with a moderate form of bronchiolitis without oxygen requirements at the time of inclusion. this must be 48 hours from the onset of the child's respiratory clinical signs. the main objective of this study is to describe the need for oxygen therapy for a young child with moderate acute bronchiolitis syndrome during home hospitalization (had) care.


Eligibility criteria:
inclusion criteria: * any infant with moderate bronchiolitis according to the has definition (except for the spo2 criterion which must be greater than or equal to 92% to avoid the patient being on oxygen therapy upon admission) * age \> 2 months and ≤ 2 years * respiratory syndrome for 48 hours * infant with a first episode of bronchiolitis * referral of the general practitioner/treating pediatrician for home hospitalisation care * parents' agreement for the choice of home hospitalisation care * non-opposition or free and informed consent of both parents to the use of the child's health data exclusion criteria: * patient not receiving health protection * comorbidities: congenital heart disease with shunt, chronic pulmonary pathology including bronchopulmonary dysplasia, neuromuscular pathology, immune deficiency, multiple disabilities congenital heart disease * refusal of one or both parents for the proposed pathway * doubts about the parents' understanding of the nature of home hospitalisation care * severe bronchiolitis or with saturation \< 92% * moderate bronchiolitis but evolving for less than 48 hours * cases of psychiatric pathologies or depressive syndrome diagnosed in the parents.
the effects of mother-infant skin-to-skin contact on stress response of preterm infants

Conditions: Preterm Infant

Summary: this study will evaluate the effect of maternal-infant skin-to-skin contact (ssc) versus routine care on general stress in preterm infants in the neonatal intensive care unit (nicu).

primary outcome of this trial to investigate the effects daily skin-to-skin contact on cumulative stress through measures salivary cortisol. the intervention group will receive mother-infant skin-to-skin contact at least 1 continuous hour everyday from infant 3 days of life until discharge. the control group will receive routine neonatal care during hospitalization except skin-to-skin contact. the concentration of salivary cortisol and other infant and parental outcomes will be measured in both groups.

Eligibility criteria:
inclusion criteria: * 31 weeks≤gestational age\<37 weeks; * birth weight ≥ 1500g; * admission age \< 24h; * no congenital malformations; * vital signs are stable and does not use ventilator and other auxiliary life support systems. exclusion criteria: * severe periventricular / intraventricular hemorrhage (grade iii); * receiving sedation or vasopressor or analgesics opiodis and corticosteroids; * mother unable to communicate and communicate normally; mother has a history of depression.

Keywords: stress response skin-to-skin contact cortisol
the prevalence and characteristics of adrenal incidentaloma

Conditions: Prevalence; Adrenal Incidentaloma

Summary: to investige the prevalence, characteristics and prognosis of adrenal incidentalomas in chinese adults.

with the development of imaging detection technology and its wide application in clinic, the detection rate of adrenal incidentaloma (ai) has been greatly improved. most ai are benign and do not have the function of autonomic hormone secretion, but about 20% of them have function and can secrete adrenal hormone autonomously. studies based on biopsy reports show that the prevalence of ai is about 2%, and the prevalence of ai detected by ct scan is 1% - 4.5%. however, most of these studies are retrospective, and there may be selection bias and other confounding factors. there is no large sample prospective study on the prevalence of ai in the general population. the purpose of this study is to prospectively include patients with adrenal incidentaloma in community physical examination population, and evaluate their function and prognosis. the research results will provide new evidence for standardized diagnosis and treatment of adrenal incidentaloma in the future.

Eligibility criteria:
inclusion criteria: ·on weekdays, the first 100 individuals, aged 18 to 78 years, taking health checkup in the community health examination center were invited to take part in the study. exclusion criteria: * with known adrenal diseases; * with continuous steroids or drug treatment that might influence cortisol secretion ordexamethasone metabolism and could not be stopped * refuse to participate in the study.

Keywords: prevalence characteristics adrenal incidentaloma
nadolol for proliferating infantile hemangiomas

Conditions: Infantile Hemangioma

Summary: the purpose of this study is to explore the efficacy and safety of nadolol in hemangiomas of infancy. the secondary objective is to assess the feasibility of conducting a randomized controlled trial comparing nadolol with corticosteroids and propranolol.

systemic corticosteroids are currently the most frequent used medication for treatment of problematic infantile hemangiomas (ih's). since june 2008, systemic propranolol has been an important addition to the therapeutic options for problematic ih, allowing decreased dependence on the systemic corticosteroids. so far, we have found excellent response with propranolol with minimal short-term side effects. studies, which compared nadolol and propranolol in children with other conditions, suggest that nadolol is safer and more efficacious than propranolol. in addition, it has better dosing schedules and less central nervous system (cns) penetration, making it suitable even for patients with suspected or proven phaces syndrome.

Eligibility criteria:
inclusion criteria: intervention group * infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement. historical control group * infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years angiogenesis marker control group * infants aged 1 month to 1 year attending dermatology clinic exclusion criteria: intervention group * patients with phaces syndrome (proven) or suspected phaces (plaque like hemangioma awaiting imaging). * children with history of hypersensitivity to beta blockers * children with personal history or family history of a first degree relative with asthma * children with known renal impairment * children with known cardiac conditions which may predispose to heart blocks * personal history of hypoglycemia * children on medications that may interact with beta blockers historical control group: * no digital photography available documenting ihs progression angiogenesis marker control group: * children with ih * children on beta blocker or systemic corticosteroids

Keywords: infantile hemangioma nadolol
surveillance for early liver injuries caused by xianlin gubao granule

Conditions: Drug-Induced Liver Injury

Summary: this is a prospective registry study to surveil early liver injuries caused by xianlin gubao granule (xlgb granule) through a non-intervention observational way. and attempt to establish a predictive model to screen susceptibilities to xlgb granule.

the primary objectives of this study include: (i) the detection of patients with serum liver biochemistry abnormalities within 8 weeks after intake of xlgb granule; (ii) the record of overall individuals with demographics, underlying diseases, physical status, medication information, clinical laboratory index, and so on; (iii) the specimen collection of surveiled individuals. (iv) the attempt to establish a predictive model to screen susceptibilities to xlgb granule.

Eligibility criteria:
inclusion criteria: 1. individuals in accordance with indications for xlgb granule, including osteoporosis, fracture, osteoarthritis, aseptic necrosis of bone and climacteric; 2. the age range of 18 to 70 years; 3. individuals taking xlgb granule over 2 weeks; 4. abnormalities of serum liver biochemistry achieving one of the criteria as follows: (i) alanine aminotransaminase (alt) or aspartate transaminase (ast) ≥2 folds of upper limit of normal (uln); (ii) total bilirubin (tbil) ≥ 2 uln; (iii) alkaline phosphatase (alp) ≥ 2 uln; 5. individuals can provide informed consent form. exclusion criteria: 1. individuals without indications for xlgb granule; 2. unconformity to the xlgb granule drug label; 3. individual taking xlgb granule less than 2 weeks; 4. individuals taking other hepatotoxic drugs combined with xlgb granule, simultaneously; 5. unconformity to the diagnostic standard for herb-induced liver injury (the guideline for diagnosis and treatment of herb-induced liver injury, rpgip-2016cn003）.

Keywords: drug-induced liver injury
a study on the possible health effects of lean fish, fatty fish and lean meat intake in non-obese adults

Conditions: Metabolic Disorders; Obesity

Summary: this study is a pilot study to investigate whether intake of lean or fatty fish, or lean meat would affect parameters related to health in healthy non-obese adults, and will serve as basis for future calculation of group sizes in coming studies. participants consumed 750g/week of fillets of fish or meat for 4 weeks. hypothesis: high intake of either lean or fatty fish will not affect serum concentrations of lipids and inflammatory markers as well as improve glucose tolerance during the 4 week intervention period when compared to lean meat intake.


Eligibility criteria:
inclusion criteria: * adults * non-obese * healthy exclusion criteria: * diabetes * diagnosed diseases of the intestine or cardiovacular system
a study to assess the acceptability and usability of a new device for intradermal vaccination

Conditions: Pain; Vaccination Adverse Event

Summary: the aim of this study was to assess the acceptability and usability of a newly developed intradermal device in healthy adults


Eligibility criteria:
inclusion criteria: * healthy adults exclusion criteria: * people who have regular experience with needle injections, e.g. diabetic patients * pregnant women
davinci registry(distinctly assess vision in coronary intervention)

Conditions: Coronary Disease

Summary: prospective internet-registry, postmarketing-surveillance, registration and follow-up of patients after multi-link vision™ - stent implantation

a non-randomized prospective evaluation of the multi-link rx vision tm coronary stent system in the treatment of patients with de novo native coronary artery lesions

Eligibility criteria:
inclusion criteria: * women and men age \>18 years, intention to treat all stenosis with multi-link visiontm stents, documented patient consent exclusion criteria: * no multi-link vision™ stent implanted, life expectation \>9 m, cardiogenic shock, stemi, nstemi or unstable angina pectoris with pathologic markers within the last 48 hours, intolerance of clopidogrel/ tiklopidin
patterns of congenital heart diseases at sohag university hospital

Conditions: Congenital Heart Disease

Summary: congenital heart diseases (chd) are structural or functional heart diseases that present at birth even if it is discovered later in life . congenital heart disease is caused by disturbance in the normal development of the heart especially during the first 6 weeks of pregnancy. researchers aren't sure about the exact cause , but they think genetics , certain medical conditions , some medications and environmental factors, such as smoking, may play a role . chd in many cases may be asymptomatic and discovered accidently during the routine examination or may be presented by some clinical manifestations (e.g. cyanosis or murmers) and /or complications (e.g. heart failure manifestations : tachycardia , tachypnea , dyspnea during feeding , diaphoresis especially during feeding ,restlessness, irritability , hepatomegaly , and failure to thrive) . recently diagnosis of congenital heart disease is better by using advanced technology e.g. echocardiography, magnetic resonance imaging (mri), cardiac catheterization, angiography, and radio-active isotopes . and early diagnosis is very important as regard the manangement of the disease . as medical care and surgical interventions have advanced over time, the treatment of many abnormalities is now available . and many infants and children with congenital heart defects are living longer and healthier lives. many are living into adulthood, requiring ongoing, lifelong medical care for their conditions . so information about different aspects of chd is very important for planning health programs for long-term care and maintenance for these cases .


Eligibility criteria:
inclusion criteria: * all children from date of birth to age of 12 years old including both genders diagnosed to have chd . exclusion criteria: * more than 12 years old . * acquired heart diseases * children with heart rate abnormalities
pediatric eeg monitoring

Conditions: Pediatric ALL; Epilepsy

Summary: the purpose of this study is to understand if a new, smart, wireless eeg developed by our team can be used to monitor the continuous electrical activity of the brain in the icu and emu and whether it works as well as the current standard, wired eegs.

the investigators propose to 1) optimize these devices for use in pediatric icu patients, 2) demonstrate safety, reliability, and accuracy of these devices for continuous icu eeg signal measurements, and 3) demonstrate these devices are preferred by patients and parents to current eeg devices. once validated, such sensors could fundamentally change the way patients are monitored by eeg in the icu, allowing wireless, continuous, real-time detection of brain wave activity in icu patients, reducing limitations in mobility as well as access by staff and caregivers to the patient, and ultimately offering opportunity to reduce morbidity and mortality in icu patients.

Eligibility criteria:
inclusion criteria: * participants must be admitted to the picu or emu at lurie children's and are prescribed an eeg as part of their standard of care. exclusion criteria: * anyone with a skin abnormality that would potentially increase the risk of device use will be excluded. * ages 18 years or older. * any patient or family determined by an attending physician or bedside care team to be too unstable (patient) or experiencing too much stress (family) will not be approached for recruitment.